CN Patent

CN121620374A — 包含menin抑制剂的药物组合物

Assigned to Kura Oncology Inc · Expires 2026-03-06 · 0y expired

What this patent protects

本文提供了(S)‑4‑甲基‑5‑((4‑((2‑(甲基氨基)‑6‑(2,2,2‑三氟乙基)噻吩并[2,3‑d]嘧啶‑4‑基)氨基)哌啶‑1‑基)甲基)‑1‑(2‑(4‑(甲基磺酰基)哌嗪‑1‑基)丙基)‑1H‑吲哚‑2‑甲腈或其溶剂化物的结晶形式，制备此类形式的方法和包含此类形式的药物组合物。

USPTO Abstract

本文提供了(S)‑4‑甲基‑5‑((4‑((2‑(甲基氨基)‑6‑(2,2,2‑三氟乙基)噻吩并[2,3‑d]嘧啶‑4‑基)氨基)哌啶‑1‑基)甲基)‑1‑(2‑(4‑(甲基磺酰基)哌嗪‑1‑基)丙基)‑1H‑吲哚‑2‑甲腈或其溶剂化物的结晶形式，制备此类形式的方法和包含此类形式的药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN121620374A
Jurisdiction
CN
Classification
—
Expires
2026-03-06
Drug substance claim
No
Drug product claim
No
Assignee
Kura Oncology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.